-
Cost-Effectiveness of Sulopenem vs. Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Decision Analysis
Sep 9, 2025, 16:22 PM -
A Cost-Minimization and Budget Impact Analysis of NT-proBNP Screening Test for Risk Assessment and Monitoring of Pulmonary Arterial Hypertension (PAH) Patients in Australian Healthcare Setting
Sep 9, 2025, 16:22 PM -
Reducing the Rare Disease Diagnostic Odyssey: Identifying Potential Pulmonary Arterial Hypertension Patients Using the Problem List of Diagnosed Patients
Sep 9, 2025, 16:22 PM -
Variations in Mortality Across Clinical Trials: A Review of Statistical Methods for Adjusting for the Effect of the COVID-19 Pandemic
Sep 9, 2025, 16:22 PM -
Impact of Tafamidis Use in Colombian Patients Diagnosed With ATTR-CM on Health-Related Quality of Life During One Year of Follow-up: Real-World Study in Colombia
Sep 9, 2025, 16:22 PM -
Trends in Hospital Treatment of Follicular Lymphoma in Germany
Sep 9, 2025, 16:22 PM -
Microcosting Analysis of Oral, Subcutaneous, and Intravenous Second-line Multiple Sclerosis Treatments Administered at Home or in Hospital
Sep 9, 2025, 16:22 PM -
Clinical and Economic Outcomes of Cannabis-Based Formulations (CBD and CBD/CBG) for Autism Spectrum Disorder (ASD): A HEOR Model Study Analysis
Sep 9, 2025, 16:22 PM -
Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-Term Treatment Effect: An Example in Alzheimer’s Disease
Sep 9, 2025, 16:22 PM -
Parental Vaccine Hesitancy in Children With Comorbidities: A Comparative Analysis
Sep 9, 2025, 16:22 PM -
Strategies for More Cost-Effective HrHPV Screening: A Simulation Study of Pooled Testing Based on Real-World Data in Low- and Middle-Income Countries
Sep 9, 2025, 16:22 PM -
Impact of Disease Progression on Healthcare Resource Utilization and Quality of Life in Patients With Hypertrophic Cardiomyopathy: A Real-World Cross-Sectional Survey
Sep 9, 2025, 16:22 PM -
HTA for Obesity and T2DM Indications: A Review and Recommendations for Future Appraisals
Sep 9, 2025, 16:22 PM -
A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia
Sep 9, 2025, 16:22 PM -
Development and Validation of a Machine Learning Model for Predicting French HAS ASMR Ratings Using Product and Disease Characteristics
Sep 9, 2025, 16:22 PM -
Laboratory Testing Patterns in Patients With Breast Cancer Treated With CDK4/6 Inhibitors: A Multi-Country Electronic Health Record Study From the UK, Germany, and Japan
Sep 9, 2025, 16:22 PM -
Indirect Treatment Comparison of Biochemical Control Between Pasireotide Long-Acting Release and Pegvisomant as Second-Line Therapies for Acromegaly, Based on Real-World Evidence
Sep 9, 2025, 16:22 PM -
Building the Bridge to Access: Leveraging RWE From Early Access Schemes to Reimbursement in Gene and Cell Therapies
Sep 9, 2025, 16:22 PM -
Environmental Impact of Intravenous vs. Oral Chemotherapy in France: A 1000-Patient Model-Based Assessment
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Adjuvant Alectinib vs. Platinum-Based Chemotherapy in Resected Stage IB-IIIA ALK-Positive NSCLC: A French Health Economic Evaluation
Sep 9, 2025, 16:22 PM